Referring to a ciclopirano derived Compound of formula (iv), where q is n or CH, A1A and r1b are c1-c6 alkyl, haloalquilo C1 - C6, hidroxialquilo C1 - C6, among others, r1c is H or Oh 2a, R2B, R2c and R2D are h, halogen, Oh, among others R3A, r3b, R3C R3D are h, halogen, Oh, among others.Preferred compounds are (1R, 2S) - 2 - {[(2,4 - dimetilpirimidin - 5 - il) oxy] methyl] - N - (5 - fluoropiridin - 2 (IL - 2 fenilciclopropancarboxamida) -, (1R, 2S) - N - (5 - cloropiridin - 2 (IL - 2) {[(2,4 - dimetilpirimidin - 5 - il) oxy] methyl] - 2 - fenilciclopropancarboxamida, (1R, 2S) - N - (3 - (dimethylamino) phenyl] - 2 - {[(2,4 - dimetilpirimidin - 5 - il) oxy] methyl] - 2 - fenilciclopropancarboxamida, among others.It also relates to a Pharmaceutical composition. These compounds have on the Orexin receptor antagonist activityREFERIDA A UN COMPUESTO DERIVADO DE CICLOPIRANO DE FORMULA (IV), DONDE Q ES CH O N R1a Y R1b SON ALQUILO C1-C6, HALOALQUILO C1-C6, HIDROXIALQUILO C1-C6, ENTRE OTROS R1c ES H U OH R2a, R2b, R2c Y R2d SON H, HALOGENO, OH, ENTRE OTROS R3a, R3b, R3c Y R3d SON H, HALOGENO, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (1R,2S)-2-{[(2,4-DIMETILPIRIMIDIN-5-IL)OXI]METIL}-N-(5-FLUOROPIRIDIN-2-IL)-2-FENILCICLOPROPANCARBOXAMIDA, (1R,2S)-N-(5-CLOROPIRIDIN-2-IL)-2-{[(2,4-DIMETILPIRIMIDIN-5-IL)OXI]METIL}-2-FENILCICLOPROPANCARBOXAMIDA, (1R,2S)-N-(3-(DIMETILAMINO)FENIL]-2-{[(2,4-DIMETILPIRIMIDIN-5-IL)OXI]METIL}-2-FENILCICLOPROPANCARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD ANTAGONISTA SOBRE EL RECEPTOR DE OREXINA
